Unknown PHASE2 INTERVENTIONAL 1-arm NCT03086785

Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer

Sponsor: Hebei Medical University Fourth Hospital

Interventions Apatinib

Updated 8 times since 2017 Last updated: Jan 14, 2018 Started: Nov 24, 2016 Primary completion: Nov 30, 2018 Completion: May 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Breast Cancer Metastatic, this trial is ongoing. The trial is conducted by Hebei Medical University Fourth Hospital and has accumulated 8 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Feb 2020 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status

▶ Show 3 earlier versions

Jun 2018 — Feb 2020 [monthly]

Recruiting PHASE2
Feb 2018 — Jun 2018 [monthly]

Recruiting PHASE2
Apr 2017 — Feb 2018 [monthly]

Recruiting PHASE2

First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hebei Medical University Fourth Hospital

Data source: Hebei Medical University Fourth Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shijiazhuang, China